Major Depressive Disorder (MDD)

• People with depression often have low allopregnanolone levels.
• Reduced GABAergic tone may contribute to anxiety, insomnia, and emotional dysregulation.

Brexanolone (a synthetic form of allopregnanolone) has been FDA-approved to treat postpartum depression.

Postpartum Depression (PPD)

• Progesterone and allopregnanolone drop sharply after childbirth.
• This hormonal crash can trigger depressive symptoms in sensitive individuals.

Symptoms:

• Anxiety, sadness, sleep disturbances, intrusive thoughts

Premenstrual Dysphoric Disorder (PMDD)

• Women with PMDD may have abnormal sensitivity to natural fluctuations in allopregnanolone during the menstrual cycle.
• Not necessarily low levels — the issue lies in neural response to the hormone.

• Allopregnanolone acts on GABA-A receptors to promote calm and relaxation.
• Deficiencies or resistance are linked to:
  • Generalized anxiety disorder (GAD)
  • Panic disorder
  • PTSD (post-traumatic stress disorder)

• Especially catamenial epilepsy (seizures linked to the menstrual cycle).
• Fluctuations in allopregnanolone can lower seizure threshold during certain times of the cycle (e.g., luteal phase or withdrawal).

• Reduced levels may play a role in:
  • Alzheimer’s disease (neuroinflammation and impaired neurogenesis)
  • Parkinson’s disease
• Experimental therapies aim to use allopregnanolone to promote neuroregeneration.

• Because allopregnanolone has sedative effects, low levels are associated with:
  • Trouble falling asleep
  • Poor sleep quality
  • Sleep disturbances due to anxiety or hormonal fluctuations